Department of Population Health Sciences, University of Bristol, Bristol, UK.
Fetal Medicine Unit, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Health Technol Assess. 2023 Sep;27(15):1-83. doi: 10.3310/AQTF4490.
Antidepressants are commonly prescribed during pregnancy, despite a lack of evidence from randomised trials on the benefits or risks. Some studies have reported associations of antidepressants during pregnancy with adverse offspring neurodevelopment, but whether or not such associations are causal is unclear.
To study the associations of antidepressants for depression in pregnancy with outcomes using multiple methods to strengthen causal inference.
This was an observational cohort design using multiple methods to strengthen causal inference, including multivariable regression, propensity score matching, instrumental variable analysis, negative control exposures, comparison across indications and exposure discordant pregnancies analysis.
This took place in UK general practice.
Participants were pregnant women with depression.
The interventions were initiation of antidepressants in pregnancy compared with no initiation, and continuation of antidepressants in pregnancy compared with discontinuation.
The maternal outcome measures were the use of primary care and secondary mental health services during pregnancy, and during four 6-month follow-up periods up to 24 months after pregnancy, and antidepressant prescription status 24 months following pregnancy. The child outcome measures were diagnosis of autism, diagnosis of attention deficit hyperactivity disorder and intellectual disability.
UK Clinical Practice Research Datalink.
Data on 80,103 pregnancies were used to study maternal primary care outcomes and were linked to 34,274 children with at least 4-year follow-up for neurodevelopmental outcomes. Women who initiated or continued antidepressants during pregnancy were more likely to have contact with primary and secondary health-care services during and after pregnancy and more likely to be prescribed an antidepressant 2 years following the end of pregnancy than women who did not initiate or continue antidepressants during pregnancy (odds ratio 2.16, 95% confidence interval 1.95 to 2.39; odds ratio 2.40, 95% confidence interval 2.27 to 2.53). There was little evidence for any substantial association with autism (odds ratio 1.10, 95% confidence interval 0.90 to 1.35; odds ratio 1.06, 95% confidence interval 0.84 to 1.32), attention deficit hyperactivity disorder (odds ratio 1.02, 95% confidence interval 0.80 to 1.29; odds ratio 0.97, 95% confidence interval 0.75 to 1.25) or intellectual disability (odds ratio 0.81, 95% confidence interval 0.55 to 1.19; odds ratio 0.89, 95% confidence interval 0.61 to 1.31) in children of women who continued antidepressants compared with those who discontinued antidepressants. There was inconsistent evidence of an association between initiation of antidepressants in pregnancy and diagnosis of autism in offspring (odds ratio 1.23, 95% confidence interval 0.85 to 1.78; odds ratio 1.64, 95% confidence interval 1.01 to 2.66) but not attention deficit hyperactivity disorder or intellectual disability; however, but results were imprecise owing to smaller numbers.
Several causal-inference analyses lacked precision owing to limited numbers. In addition, adherence to the prescribed treatment was not measured.
Women prescribed antidepressants during pregnancy had greater service use during and after pregnancy than those not prescribed antidepressants. The evidence against any substantial association with autism, attention deficit hyperactivity disorder or intellectual disability in the children of women who continued compared with those who discontinued antidepressants in pregnancy is reassuring. Potential association of initiation of antidepressants during pregnancy with offspring autism needs further investigation.
Further research on larger samples could increase the robustness and precision of these findings. These methods applied could be a template for future pharmaco-epidemiological investigation of other pregnancy-related prescribing safety concerns.
This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (15/80/19) and will be published in full in ; Vol. 27, No. 15. See the NIHR Journals Library website for further project information.
尽管随机试验并未证明抗抑郁药在妊娠期间的益处或风险,但抗抑郁药仍常被用于治疗妊娠期间的抑郁症。一些研究报告称,妊娠期间使用抗抑郁药与后代神经发育不良有关,但这种关联是否具有因果关系尚不清楚。
使用多种方法加强因果推断,研究妊娠期间使用抗抑郁药治疗抑郁症与结局之间的关联。
这是一项观察性队列设计,使用多种方法加强因果推断,包括多变量回归、倾向评分匹配、工具变量分析、阴性对照暴露、不同适应证比较和暴露不一致妊娠分析。
在英国普通实践中进行。
患有抑郁症的孕妇。
干预措施为妊娠期间开始使用抗抑郁药与未开始使用相比,以及妊娠期间继续使用抗抑郁药与停止使用相比。
母体结局测量指标为妊娠期间和妊娠后 24 个月的 4 个 6 个月随访期间使用初级保健和二级精神卫生服务的情况,以及妊娠后 24 个月时抗抑郁药的处方情况。儿童结局测量指标为自闭症、注意缺陷多动障碍和智力残疾的诊断。
英国临床实践研究数据链接。
使用 80103 例妊娠数据来研究母体初级保健结局,并将其与至少有 4 年神经发育结局随访的 34274 例儿童进行了链接。与未开始或停止使用抗抑郁药的孕妇相比,开始或继续使用抗抑郁药的孕妇在妊娠期间和妊娠后更有可能接触初级和二级医疗保健服务,并且在妊娠结束后 2 年内更有可能被开抗抑郁药(比值比 2.16,95%置信区间 1.95 至 2.39;比值比 2.40,95%置信区间 2.27 至 2.53)。对于自闭症(比值比 1.10,95%置信区间 0.90 至 1.35;比值比 1.06,95%置信区间 0.84 至 1.32)、注意缺陷多动障碍(比值比 1.02,95%置信区间 0.80 至 1.29;比值比 0.97,95%置信区间 0.75 至 1.25)或智力残疾(比值比 0.81,95%置信区间 0.55 至 1.19;比值比 0.89,95%置信区间 0.61 至 1.31),继续使用抗抑郁药的孕妇的孩子中几乎没有证据表明与停药的孕妇相比存在显著关联。在妊娠期间开始使用抗抑郁药与自闭症诊断之间存在关联的证据不一致(比值比 1.23,95%置信区间 0.85 至 1.78;比值比 1.64,95%置信区间 1.01 至 2.66),但与注意缺陷多动障碍或智力残疾无关;然而,由于数量较少,结果不太准确。
由于数量有限,几种因果推断分析缺乏精确性。此外,未测量对规定治疗的依从性。
与未开抗抑郁药的孕妇相比,开抗抑郁药的孕妇在妊娠期间和妊娠后使用的服务更多。继续使用抗抑郁药的孕妇与停止使用抗抑郁药的孕妇相比,其子女患自闭症、注意缺陷多动障碍或智力残疾的证据令人放心。需要进一步研究妊娠期间开始使用抗抑郁药与后代自闭症之间的潜在关联。
进一步研究更大的样本可以提高这些发现的稳健性和精确性。这些应用的方法可以成为未来与妊娠相关药物使用安全性问题相关的药物流行病学研究的模板。
该项目由英国国家卫生与保健研究所(NIHR)卫生技术评估计划(15/80/19)资助,将在;第 27 卷,第 15 期。有关该项目的更多信息,请访问 NIHR 期刊库网站。